Cargando…

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

BACKGROUND: Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option for CTEPH. METHODS: In this multicentre, rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogo, Takeshi, Shimokawahara, Hiroto, Kinoshita, Hideyuki, Sakao, Seiichiro, Abe, Kohtaro, Matoba, Satoaki, Motoki, Hirohiko, Takama, Noriaki, Ako, Junya, Ikeda, Yasuhiro, Joho, Shuji, Maki, Hisataka, Saeki, Takahiro, Sugano, Teruyasu, Tsujino, Ichizo, Yoshioka, Koichiro, Shiota, Naoki, Tanaka, Shinichi, Yamamoto, Chieko, Tanabe, Nobuhiro, Tatsumi, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260121/ https://www.ncbi.nlm.nih.gov/pubmed/34824052 http://dx.doi.org/10.1183/13993003.01694-2021

Ejemplares similares

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis
por: Sakao, Seiichiro, et al.
Publicado: (2019)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation
por: Sakao, Seiichiro, et al.
Publicado: (2009)

The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations
por: Sakao, Seiichiro, et al.
Publicado: (2014)

Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertension　― Multicenter Study in Japan ―
por: Takeyasu, Rika, et al.
Publicado: (2020)

Determinants of an elevated pulmonary arterial pressure in patients with pulmonary arterial hypertension
por: Sakao, Seiichiro, et al.
Publicado: (2015)

Thrombotic Lesions are Associated with Poor Outcomes after Endovascular Treatment in Patients with Non-Acute Aortoiliac Total Occlusions
por: Kadoya, Yoshito, et al.
Publicado: (2021)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

The Bezold–Jarisch reflex in a patient with coronary spastic angina
por: Sakai, Chieko, et al.
Publicado: (2020)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells
por: Sakao, Seiichiro, et al.
Publicado: (2011)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Granulocyte colony stimulating factor-associated aortitis evaluated via multiple imaging modalities including vascular echography: a case report
por: Harada, Mikiko, et al.
Publicado: (2020)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
por: Luo, Shun-bin, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

The Development of Marked Collateral Circulation due to Inferior Vena Cava Filter Occlusion in a Patient with Chronic Thromboembolic Pulmonary Hypertension Complicated with Anti-phospholipid Syndrome
por: Kasai, Hajime, et al.
Publicado: (2017)

The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan
por: Takahashi, Yukiko, et al.
Publicado: (2021)

An estimation of molecular dynamic behaviour in a liquid using core-loss spectroscopy
por: Matsui, Yoshiki, et al.
Publicado: (2013)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
por: Lattanzio, Mariangela, et al.
Publicado: (2022)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Absent fourth heart sound as a marker of adverse events in hypertrophic cardiomyopathy with sinus rhythm
por: Sakai, Chieko, et al.
Publicado: (2022)

Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR)
por: Tamura, Yuichi, et al.
Publicado: (2021)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

The Role of Matrix Metalloproteinase in the Intimal Sarcoma-Like Cells Derived from Endarterectomized Tissues from a Chronic Thromboembolic Pulmonary Hypertension Patient
por: Jujo, Takayuki, et al.
Publicado: (2014)

Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
por: Naito, Akira, et al.
Publicado: (2014)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Treatment of Vascular Injury During Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension
por: Ejiri, Kentaro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84h0tpheaqhv6blu80r30s25hq